We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
34. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
36. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
37. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
38. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
39. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
41. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
42. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
43. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
45. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
46. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
47. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
48. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
49. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
50. Cow’s milk allergy: the future
- Dr. Carina Venter
-
51. Cow's milk allergy: management
- Dr. Carina Venter
-
52. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
53. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
54. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
55. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
56. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
57. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
58. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
59. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
60. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
61. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
63. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
64. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
65. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
66. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
67. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
68. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
69. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
70. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
71. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
72. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
73. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
74. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
75. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
76. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
77. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
78. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
79. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
80. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
81. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
82. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
83. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
84. AI and big data in drug discovery
- Mr. Ed Addison
-
85. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
86. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
87. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
88. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
89. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
90. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
91. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
92. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
93. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
94. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
95. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
96. New drugs for asthma
- Prof. Peter Barnes
-
97. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
98. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- B cells in autoimmune diseases
- B cell development
- Histopathology
- B cell tolerance checkpoints in autoimmune disease
- B cell activating factor (BAFF) (1)
- B cell activating factor (BAFF) (2)
- B cell activating factor (BAFF) (3)
- CD40/CD40L (1)
- CD40/CD40L (2)
- Toll-like receptors (1)
- Toll-like receptors (2)
- Toll-like receptors (3)
- CD19
- Thymic B cells (1)
- Thymic B cells (2)
- Histopathology of B cells in autoimmune diseases
- Tissue-infiltrating B cells (1)
- Tissue-infiltrating B cells (2)
- Tissue-infiltrating B cells (3)
- Antibody-dependent B cell functions in autoimmune diseases (1)
- Antibody-dependent B cell function
- Antibody-dependent B cell function (IgG) (1)
- Antibody-dependent B cell function (IgG) (2)
- Antibody-dependent B cell function (IgG) (3)
- Antibody-dependent B cell function (IgM)
- Antibody-dependent B cell function (Mem B)
- Antibody-dependent B cell functions in autoimmune diseases (2)
- Antigen presentation
- Cytokine production
- Lymphotoxin
- IL-6 (1)
- IL-6 (2)
- IL-6 (3)
- GM-CSF (1)
- GM-CSF (2)
- Interferon gamma (1)
- Interferon gamma (2)
- Regulatory B cells (1)
- Regulatory B cells: subsets of B cells (1)
- Regulatory B cells: subsets of B cells (2)
- Regulatory B cells (2)
- Regulatory B cells: IL10 production and disease progression
- Regulatory B cells: drug screening
- Regulatory B cells: IL-35-producing B cells
- Regulatory B cells: IL-21-producing B cells
- Targeting B cells in autoimmune diseases
- B cell depletion therapy (1)
- B cell depletion therapy (2)
- B cell depletion therapy (3)
- Immune checkpoints therapy (1)
- Immune checkpoints therapy (2)
- Immune checkpoints therapy (3)
- Acknowledgements
Topics Covered
- B cell development
- B cells in autoimmune diseases
- BAFF
- CD40
- Thymic B cells
- Antibody-dependent B cell functions
- Antigen presentation
- Cytokine production
- IL6
- Regulatory B cells
- B cell depletion therapy
- Immune checkpoints therapy
Links
Series:
- The Immune System - Key Concepts and Questions
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Lin, X. (2023, October 31). B cells at the crossroads of autoimmune diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/ZJEE7936.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Xiang Lin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone, I'm Lin Xiang
from the School of
Chinese Medicine,
the University of Hong Kong.
Today, I'd like to
talk about the role of
B cells in autoimmune diseases.
0:13
The simplified immune response
against autoantigens.
The B cells receive
the stimulants via
the B cell receptor,
they then present then
antigens to cognate T cells
and further promote
T cell differentiation by
costimulatory molecules
and cytokine production.
Well, these B cells, however,
mature into autoantibody-producing
plasma cells.
This cascade happens throughout
the disease progression.
Now, extensive studies
have suggested
a central role of B cells in
the autoimmune pathogenesis.
Because loss of B cell tolerance
can result in increased
serum levels of
autoantibodies and enhanced
effector T cell response and
tissue damage in patients.
Today we'll walk
through the overview of
these regulated B cell responses
in the development
of autoimmunity.
1:03
As you can see, the
B cell tolerance
is established throughout
the B cell
developmental stages in
both bone marrow and the
peripheral lymphoid organs.
From the prob-B to
pre-B cell stages,
they will migrate
into the periphery
and then become
immature B cells,
through to the maturation and
the differentiation stages,
while part of the plasma
cells will migrate back to
the bone marrow
through chemotaxis.
Although approximately
55% to 75% of early
immature B cells will
exhibit self-reactivity,
most of the other
reactive B cells are
eliminated by multiple
checkpoints accordingly,
which we will explain
in later slides.
Histopathologically, the
massive B cells are detected in